Annexin derivative with endogenous chelation sites

Details Annexin derivative with endogenous chelation sites Annexin derivative with endogenous chelation sites

1999-06-01

2001-11-27

Huff, Sheela (Department: 1642)

Chemistry: natural resins or derivatives; peptides or proteins;

Peptides of 3 to 100 amino acid residues

25 or more amino acid residues in defined sequence

C530S300000, C424S001110, C424S001650, C424S001690, C424S009100

Reexamination Certificate

active

06323313

ABSTRACT:

FIELD OF THE INVENTION
The present invention relates to annexin derivatives having chelation sites, radiolabeled annexin derivatives, and imaging methods using radiolabeled annexin derivatives.
BACKGROUND OF THE INVENTION
The formation of vascular thrombi is a significant complicating factor for atherosclerosis and coronary trauma or disease. Techniques for determining the presence of vascular thrombi include invasive techniques that are often cumbersome and fail to detect thrombi with good sensitivity and specificity. Available non-invasive techniques are often of limited value and fail to image arterial thrombi. Common arterial thrombosis imaging use radionuclide methods that are complex and time consuming, and limited in their practical utility. More importantly, these methods generally fail to detect small thrombi which are of significant clinical importance, particularly in coronary arterial thrombi.
Activated platelets associated with vascular thrombi, express phosphatidylserine, an anionic phospholipid, in an amount significantly greater than quiescent platelets, which express little, if any, phosphatidylserine. Annexins are a class of proteins that are characterized by calcium-mediated binding to anionic phospholipids. Annexin V is a human protein of 319 amino acids with a molecular weight of 36,000 Daltons and binds to phosphatidylserine with a high affinity (K
d
=7 nM/L). Accordingly, annexin V offers the potential for selective targeting of platelet thrombi. Furthermore, because there is virtually no circulating annexin V endogenous pool to compete for binding sites on thrombi or to dilute exogenously administered annexin V, annexin V is an attractive candidate for the non-invasive detection of vascular thrombi. Recently, radiolabeled annexins derivatives have been used to image vascular thrombi in vivo. Stratton et al.,
Circulation,
92:3113-3121, 1995.
In addition to its association with vascular thrombi cell surface expression of phosphatidylserine also occurs during apoptosis. One of the earliest events in programmed cell death is the externalization of phosphatidylserine, a membrane phospholipid normally restricted to the inner leaflet of the lipid bilayer. Cells undergoing apoptosis redistribute phosphatidylserine from the inner leaflet of the plasma membrane lipid bilayer to the outer leaflet.
Cell death can occur either through necrosis, which results in uncontrolled release of a variety of intracellular substances, or through apoptosis, which is an orchestrated sequence leaving little cellular residue. Through apoptosis, cellular debris is absorbed by neighboring cells without damage to adjacent tissue or extracellular matrix. Apoptosis (or programmed cell death) plays an important role in a number of physiological events including embryogenesis, regulation of the immune system, and homeostasis. Programmed cell death also plays a role in the pathogenesis of a number of disorders including AIDS and other viral illnesses, cerebral and myocardio ischemia, autoimmune and neurodegenerative diseases, organ and bone marrow transplant rejection, and tumor response to chemotherapy and radiation.
Apoptosis has been determined in histological sections with in situ staining of DNA breaks, formed by the cleavage of chromatin by endonucleases, by terminal deoxynucleotidyl-transferase-mediated deoxyuridine triphosphate-biotin nick-and labeling imaging.
Because annexin has a high affinity for cell membranes expressing phosphatidylserine, annexin V derivatives have been utilized to detect apoptosis in hematopoietic cells, neurons, fibroblasts, endothelial cells, smooth muscle cells, carcinomas, lymphomas, all murine embryonic cell types and plant and insect cells. The utility of a radiolabeled annexin V for in vivo imaging of phosphatidylserine expression associated with apoptosis has been reported. Blankenberg et al.,
Proc. Natl. Acad. Sci. U.S.A.,
95:6349-6354, 1998. In the report, phosphatidylserine expression during programmed cell death was detected and imaged through the use of a radiolabeled annexin conjugate (
99m
Tc HYNIC-annexin V). The use of the same radiolabeled annexin conjugate for in vivo imaging of apoptosis during cardiac allograft rejection has also been reported. Vriens et al.,
The Journal of Thoracic and Cardiovascular Surgery,
116:844-853, 1998.
Despite the benefits and advantages related to the annexin-based imaging agents noted above, a need for improved annexin-based imaging agents that are effective as imaging vascular thrombi and apoptosis and more readily prepared than the currently used annexin conjugates. The present invention seeks to fulfill these needs and provides further related advantages.
SUMMARY OF THE INVENTION
In one aspect, the present invention provides a modified annexin having an N-terminal chelation site. By virtue of the chelation site, the modified annexin readily chelates a radionuclide to provide a radiolabeled annexin. In a preferred embodiment, the modified annexin includes an endogenous chelation site that is formed recombinantly. Methods for forming the modified annexin and radiolabeled annexin are also provided.
In another aspect of the present invention, a method for imaging vascular thrombi is provided. In the method, vascular thrombi are imaged using a modified annexin having an N-terminal chelation site to which is complexed a radionuclide.
In a further aspect, the present invention provides a method for imaging apoptosis. In the method, apoptosis is imaged using a modified annexin having an N-terminal chelation site to which is complexed a radionuclide.


REFERENCES:
patent: 5849261 (1998-12-01), Dean et al.
patent: 5968477 (1999-10-01), Kasina et al.
patent: WO 95/19791 (1995-07-01), None
patent: WO 95/34315 (1995-12-01), None
patent: WO 96/17618 (1996-06-01), None
patent: WO 98/04294 (1998-02-01), None
Giblin, M.F., et al., “Synthesis and Characterization of Rhenium-Complexed &agr;-Melanotropin Analogs,”Bioconjugate Chem.,vol. 8, No. 3, 1997, pp. 347-353.
Stalteri, M.A., et al., “Comparison of the Stability of Technetium-Labeled Peptides to Challenge with Cysteine,”Bioconjugate Chem.,vol. 10, No. 1, 1999, pp. 130-136.
Blankenberg, F.G., et al., “Imaging of Apoptosis (Programmed Cell Death) with99mTc Annexin V,”The Journal of Nuclear Medicine,vol. 40, No. 1, Jan. 1999, pp. 184-191.
Blankenberg, F.G., et al., “In Vivo Detection and Imaging of Phosphatidylserine Expression During Programmed Cell Death,”Proceedings of the National Academy of Sciences,vol. 95, May 1998, pp. 6349-6354.
George, A.J.T., et al., “Radiometal Labeling of Recombinant Proteins by a Genetically Engineered Minimal Chelation Site: Technetium-99m Coordination by Single-Chain Fv Antibody Fusion Proteins Through a C-Terminal Cysteinyl Peptide,”Proceedings of the national Academy of Sciences,vol. 92, Aug. 1995, pp. 8358-8362.
Huston, J.S., et al., “Single-Chain Fv Radioimmunotargeting,”The Quarterly Journal of Nuclear Medicine,vol. 40, No. 3, Sep. 1996, pp. 320-333.
Liberatore, M., et al., “Efficient One-Step Direct Labelling of Recombinant Antibodies with Technetium-99m,”European Journal of Nuclear Medicine,vol. 22, No. 11, Nov. 1995, pp. 1326-1329.
Stratton, J.R., et al., “Selective Uptake of Radiolabeled Annexin V on Acute Porcine Left Atrial Thrombi,”Circulation,vol. 92, No. 10, Nov. 15, 1995, pp. 3113-3121.
Vriens, P.W., et al., “The Use of Technetium TC99M Annexin V for In Vivo Imaging of Apoptosis During Cardiac Allograft Rejection,”The Journal of Thoracic and Cardiovascular Surgery,vol. 116, No. 5, Nov. 1998, pp. 844-853.

Affiliated with

Also associated with

Rating

Annexin derivative with endogenous chelation sites does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Annexin derivative with endogenous chelation sites, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Annexin derivative with endogenous chelation sites will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2574349